News | ACC | April 03, 2022

ACC22: Interim Findings Show Promise in Decreasing Shortness of Breath From Hypertrophic Cardiomyopathy

Late-breaking research from the Smidt Heart Institute at Cedars-Sinai presented at the American College of Cardiology Scientific Session

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

Florian Rader, MD, MSc, associate professor of Cardiology and medical director of the Hypertension Center in the Smidt Heart Institute at Cedars-Sinai, presented results of an international clinical trial that shows the drug, mavacamten, alleviated the shortness of breath in patients with obstructive hypertrophic cardiomyopathy.

The genetic condition causes thickening of the heart muscle, and as a result, heart muscle cells enlarge and scarring often develops between cells. Patients with the condition typically experience shortness of breath, chest pressure, irregular heartbeat, and, although rare, sudden cardiac arrest. 

"Until now, existing treatments for hypertrophic cardiomyopathy have been suboptimal, leaving most patients symptomatic and often, in need of invasive or even open-heart surgery," said Rader, who served as site principal investigator of the clinical trial at Cedars-Sinai and lead author of the ACC late-breaking abstract. "Follow-up data from this extended clinical trial shows success in lessening the obstruction to blood flow out of the heart in hypertrophic cardiomyopathy. Along with this relief of obstruction came substantial improvements in symptoms and an important heart failure blood biomarker." 

As Rader, also co-director of the Hypertrophic Cardiomyopathy Clinic at Cedars-Sinai, explained in the late-breaking presentation, mavacamten showed preliminary success in relieving symptoms associated with the condition-specifically shortness of breath, which can be debilitating for hypertrophic cardiomyopathy patients.  

Key data from the clinical trial-shared by Rader at ACC22-includes:

·      The average age of the 231 clinical trial participants was 60 years old, and 39% of those on the trial were female.  The median follow-up was 62 weeks.

·      69% of trial participants had improved shortness of breath after 48 weeks of treatment.

·      Treatment with mavacamten was generally well tolerated, and no new safety concerns were raised during longer-term follow-up.

 

Since the condition was first described some 60 years ago, Rader says no disease-specific targeted treatment options have been developed.

While the prevalence of hypertrophic cardiomyopathy is roughly 1 in every 200 patients, Rader says the condition is thought to be widely underdiagnosed.

"A lot of patients have the condition-and often feel short of breath or palpitations-but their doctor doesn’t recognize these symptoms as stemming from hypertrophic cardiomyopathy," said Rader. "Instead, patients may be told by their physician they are out of shape, need to lose weight or are suffering from an anxiety condition." 

The correct approach, Rader says, is to first pay close attention to the patient’s symptoms. If shortness of breath is a main concern, then a doctor should listen to the patient’s heart for a murmur, then follow up with an electrocardiogram, and, ultimately, an echocardiogram, which most often will lead to the correct diagnosis.  

Christine M. Albert, MD, MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, says this treatment option is specifically designed for hypertrophic cardiomyopathy-a welcome change for patients who have suffered for years.

"This is the largest and longest report of mavacamten in patients with hypertrophic cardiomyopathy," said Albert, who is also participating at ACC. "We are encouraged to learn that it once again proved safe and effective. We are excited to be at the forefront of bringing this investigational treatment to patients."

The drug was developed by Bristol Myers Squibb and is under consideration for approval by the U.S. Food and Drug Administration.

For more information: www.CedarsSinai.com

Related ACC22 Content:

ACC Scientific Session 2022 to Feature Smidt Heart Institute Experts

Find more ACC22 content here


Related Content

News | ACC

July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer ...

Home July 15, 2022
Home
Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
News | ACC
February 15, 2022 — The American College of Cardiology’s Cardiovascular Summit Virtual (CV Summit) will feature three ...
Home February 15, 2022
Home
Subscribe Now